RN
TransCode Therapeutics, Inc.
RNAZ · NASDAQ
$1.78 -4.30% (-$0.08)
1M -51.29%
Market Cap $2.05M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$2.55
43.3% upside
Trenutna cena
$1.78
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica RNAZ trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
0/9Valuation
-
N/A P/B N/A
EV/FFO N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 47.20%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
2 /100
Poor ROA 0.03%
Asset turnover 0.00x
ROIC 0.18%
Debt
42 /100
Moderate Int. coverage -6,516.48x
Current ratio 1.97x
Net debt/EBITDA N/A
Stability
25 /100
Unstable EPS volatility 161.70%
Profitable years 0
Beta 1.17x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o RNAZ
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Philippe Calais
Employees
12
Headquarters
Boston
Prihajajoči dogodki
18 NOV.
Earnings
Upcoming earnings report